PMID

Data

Article Title

Organization

Identification of High-Potency Human TLR8 and Dual TLR7/TLR8 Agonists in Pyrimidine-2,4-diamines.

University of Minnesota

Incorporation of Phosphonate into Benzonaphthyridine Toll-like Receptor 7 Agonists for Adsorption to Aluminum Hydroxide.

Genomics Institute of Novartis Research Foundation

Structure-Based Design of Human TLR8-Specific Agonists with Augmented Potency and Adjuvanticity.

University of Kansas

Structural requirements for TLR7-selective signaling by 9-(4-piperidinylalkyl)-8-oxoadenine derivatives.

Glaxosmithkline

Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines.

University of Kansas

Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.

Sumitomo Dainippon Pharma

Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.

Gilead Sciences

Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines.

University of Kansas

Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction.

TBA

Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.

University of Kansas

Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines.

University of Kansas

Synthesis and biological evaluation of 8-oxoadenine derivatives as toll-like receptor 7 agonists introducing the antedrug concept.

Dainippon Sumitomo Pharma

Toll-like receptor 7 and 8 imidazoquinoline-based agonist/antagonist pairs.

University of Minnesota

Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).

Biocon Bristol Myers Squibb Research Center (Bbrc)

Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.

Csir-Indian Institute of Chemical Biology

Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.

Roche Innovation Center Shanghai

Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an

Novartis Institutes For Biomedical Research

Spiro(isobenzofuranazetidine) Compounds for Treating Autoimmune Diseases.

Smith, Gambrell & Russell

Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9.

Csir-Indian Institute of Chemical Biology

Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.

Beijing Advanced Innovation Center For Human Brain Protection

Novel Triazatricycle Compounds for Treating Autoimmune Diseases.

Smith, Gambrell & Russell

Further hit optimization of 6-(trifluoromethyl)pyrimidin-2-amine based TLR8 modulators: Synthesis, biological evaluation and structure-activity relationships.

University of Ljubljana

Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.

Smith, Gambrell & Russell

Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.

University of Kansas

Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.

Genomics Institute of The Novartis Research Foundation

Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B.

Gilead Sciences

Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists.

University of Siena

Novel Hexahydro-1

Smith, Gambrell & Russell

Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.

University of Montana

Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).

Princ

Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.

Genomics Institute of The Novartis Research Foundation

Further exploration of the structure-activity relationship of imidazoquinolines; identification of potent C7-substituted imidazoquinolines.

University of Kansas

Human Toll-like Receptor (TLR) 8-Specific Agonistic Activity in Substituted Pyrimidine-2,4-diamines.

University of Minnesota

Rationally Designed Small-Molecule Inhibitors Targeting an Unconventional Pocket on the TLR8 Protein-Protein Interface.

The University of Tokyo

Discovery of Novel Small Molecule Dual Inhibitors Targeting Toll-Like Receptors

University of Colorado Boulder

Identification and characterization of a novel chemotype for human TLR8 inhibitors.

Freie Universit£T Berlin

Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction.

University of Minnesota

NLRP3 Modulators for the Treatment of Autoinflammatory Disorders.

Usona Institute

Design and Synthesis of N1-Modified Imidazoquinoline Agonists for Selective Activation of Toll-like Receptors 7 and 8.

University of Minnesota

Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.

University of Colorado Boulder

Binding characteristics of a radiolabeled agonist and antagonist at central nervous system alpha noradrenergic receptors.

TBA

Inhibition of adenosine deaminase by analogues of adenosine and inosine, incorporating a common heterocyclic base, 4(7)-amino-6(5)H-imidazo[4,5-d]pyridazin-7(4)one.

University of Maryland Baltimore County

Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 2: structure-activity relationship studies on the benzopyran scaffold.

Eli Lilly

Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.

University of Dundee